Related references
Note: Only part of the references are listed.An update on the CNS manifestations of neurofibromatosis type 2
Shannon Coy et al.
ACTA NEUROPATHOLOGICA (2020)
Poor prognosis associated with TERT gene alterations in meningioma is independent of the WHO classification: an individual patient data meta-analysis
Christian Mirian et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2020)
Comparative clinical and genomic analysis of neurofibromatosis type 2-associated cranial and spinal meningiomas
Alexander Pemov et al.
SCIENTIFIC REPORTS (2020)
Molecular characteristics of meningiomas
Young Suk Lee et al.
JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE (2020)
Identifying the deficiencies of current diagnostic criteria for neurofibromatosis 2 using databases of 2777 individuals with molecular testing
D. Gareth Evans et al.
GENETICS IN MEDICINE (2019)
Preclinical assessment of MEK1/2 inhibitors for neurofibromatosis type 2-associated schwannomas reveals differences in efficacy and drug resistance development
Marisa A. Fuse et al.
NEURO-ONCOLOGY (2019)
EPH receptor signaling as a novel therapeutic target in NF2-deficient meningioma
Steven P. Angus et al.
NEURO-ONCOLOGY (2018)
Targeted next-generation sequencing for differential diagnosis of neurofibromatosis type 2, schwannomatosis, and meningiomatosis
Camille Louvrier et al.
NEURO-ONCOLOGY (2018)
Clinical potential of meningioma genomic insights: a practical review for neurosurgeons
Michael Karsy et al.
NEUROSURGICAL FOCUS (2018)
Is NF2 a Key Player of the Differentially Expressed Gene Between Spinal Cord Ependymoma and Intracranial Ependymoma?
Ki Tae Kim et al.
WORLD NEUROSURGERY (2018)
Towards Molecular Classification of Meningioma: Evolving Treatment and Diagnostic Paradigms
Dustin T. Proctor et al.
WORLD NEUROSURGERY (2018)
Revisiting neurofibromatosis type 2 diagnostic criteria to exclude LZTR1-related schwannomatosis
Miriam J. Smith et al.
NEUROLOGY (2017)
Altered expression of E-Cadherin-related transcription factors indicates partial epithelial-mesenchymal transition in aggressive meningiomas
Maren Wallesch et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2017)
DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis
Felix Sahm et al.
LANCET ONCOLOGY (2017)
Genetic changes of MLH1 and MSH2 genes could explain constant findings on microsatellite instability in intracranial meningioma
Nives Pecina-Slaus et al.
TUMOR BIOLOGY (2017)
Timing of Smarcb1 and Nf2 inactivation determines schwannoma versus rhabdoid tumor development
Jeremie Vitte et al.
NATURE COMMUNICATIONS (2017)
Genomic landscape of high-grade meningiomas
Wenya Linda Bi et al.
NPJ GENOMIC MEDICINE (2017)
Classification of meningiomas-advances and controversies
Patrick N. Harter et al.
CHINESE CLINICAL ONCOLOGY (2017)
Role of Merlin/NF2 inactivation in tumor biology
A. M. Petrilli et al.
ONCOGENE (2016)
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
David N. Louis et al.
ACTA NEUROPATHOLOGICA (2016)
Genomic landscape of intracranial meningiomas
Wenya Linda Bi et al.
JOURNAL OF NEUROSURGERY (2016)
Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma
Malak Abedalthagafi et al.
NEURO-ONCOLOGY (2016)
Molecular Genetics of Intracranial Meningiomas with Emphasis on Canonical Wnt Signalling
Nives Pecina-Slaus et al.
CANCERS (2016)
Neurofibromatosis: A Review of NF1, NF2, and Schwannomatosis
Jesse Lee Kresak et al.
JOURNAL OF PEDIATRIC GENETICS (2016)
CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012
Quinn T. Ostrom et al.
NEURO-ONCOLOGY (2015)
Diagnosis, Management, and New Therapeutic Options in Childhood Neurofibromatosis Type 2 and Related Forms
Martino Ruggieri et al.
SEMINARS IN PEDIATRIC NEUROLOGY (2015)
AKT1E17K mutations cluster with meningothelial and transitional meningiomas and can be detected by SFRP1 immunohistochemistry
Felix Sahm et al.
ACTA NEUROPATHOLOGICA (2013)
Secretory meningiomas are defined by combined KLF4 K409Q and TRAF7 mutations
David E. Reuss et al.
ACTA NEUROPATHOLOGICA (2013)
Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations
Priscilla K. Brastianos et al.
NATURE GENETICS (2013)
Merlin, the NF2 Gene Product
Nives Pecina-Slaus
PATHOLOGY & ONCOLOGY RESEARCH (2013)
Genomic Analysis of Non-NF2 Meningiomas Reveals Mutations in TRAF7, KLF4, AKT1, and SMO
Victoria E. Clark et al.
SCIENCE (2013)
Communicating Hydrocephalus and Vestibular Schwannomas: Etiology, Treatment, and Long-Term Follow-Up
Qasim Al Hinai et al.
JOURNAL OF NEUROLOGICAL SURGERY PART B-SKULL BASE (2013)
Magnetic resonance imaging features of meningiomas in children and young adults: a retrospective analysis
Pedro S. Pinto et al.
JOURNAL OF NEURORADIOLOGY (2012)
Long-term follow-up of 287 meningiomas in neurofibromatosis type 2 patients: clinical, radiological, and molecular features
Stphane Goutagny et al.
NEURO-ONCOLOGY (2012)
Merlin/NF2 Suppresses Tumorigenesis by Inhibiting the E3 Ubiquitin Ligase CRL4DCAF1 in the Nucleus
Wei Li et al.
CELL (2010)
Further genotype - phenotype correlations in neurofibromatosis 2
S. K. Selvanathan et al.
CLINICAL GENETICS (2010)
Meningiomas and neurofibromatosis
Stephane Goutagny et al.
JOURNAL OF NEURO-ONCOLOGY (2010)
Hearing Improvement after Bevacizumab in Patients with Neurofibromatosis Type 2
Scott R. Plotkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Neurofibromatosis type 2 (NF2): A clinical and molecular review
D. Gareth R. Evans
ORPHANET JOURNAL OF RARE DISEASES (2009)
Contact-dependent inhibition of EGFR signaling by Nf2/Merlin
Marcello Curto et al.
JOURNAL OF CELL BIOLOGY (2007)
Merlin/neurofibromatosis type 2 suppresses growth by inhibiting the activation of Ras and Rac
Helen Morrison et al.
CANCER RESEARCH (2007)
Schwannomin inhibits tumorigenesis through direct interaction with the eukaryotic initiation factor subunit c (eIF3c)
DR Scoles et al.
HUMAN MOLECULAR GENETICS (2006)
The distribution of constitutional and somatic mutations in the neurofibromatosis 2 gene
ME Baser
HUMAN MUTATION (2006)
Merlin inhibits growth hormone-regulated Raf-ERKs pathways by binding to Grb2 protein
JY Lim et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2006)
The molecular biology of vestibular schwannomas: Dissecting the pathogenic process at the molecular level
BA Neff et al.
OTOLOGY & NEUROTOLOGY (2006)
The merlin tumor suppressor interacts with Ral guanine nucleotide dissociation stimulator and inhibits its activity
CH Ryu et al.
ONCOGENE (2005)
The location of constitutional neurofibromatosis 2 (NF2) splice site mutations is associated with the severity of NF2
ME Baser et al.
JOURNAL OF MEDICAL GENETICS (2005)
Diagnostic criteria for schwannomatosis
M MacCollin et al.
NEUROLOGY (2005)
Neurofibromatosis 2 (NF2) tumor suppressor merlin inhibits phosphatidylinositol 3-kinase through binding to PIKE-L
R Rong et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Merlin, a tumor suppressor, interacts with transactivation-responsive RNA-binding protein and inhibits its oncogenic activity
JY Lee et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Magicin, a novel cytoskeletal protein associates with the NF2 tumor suppressor merlin and Grb2
T Wiederhold et al.
ONCOGENE (2004)
cDNA microarray analysis of vestibular schwannomas
DB Welling et al.
OTOLOGY & NEUROTOLOGY (2002)
Identification of the cis-acting region in the NF2 gene promoter as a potential target for mutation and methylation-dependent silencing in schwannoma
T Kino et al.
GENES TO CELLS (2001)
Mutations and allelic loss of the NF2 gene in neurofibromatosis 2-associated skin tumors
L Kluwe et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2000)
Share Paper
